Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pioglitazone Reduces β Amyloid Levels <i>via</i> Inhibition of PPARγ Phosphorylation in a Neuronal Model of Alzheimer's Disease.
|
31379559 |
2019 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this review, we have shed some light on the recent progress of how, PPARγ agonist selectively modulated different cellular targets in AD and its amazing potential in the treatment of AD.
|
30152284 |
2019 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We and others have shown that PPARγ agonism improves cognition in preclinical models of AD as well as in several pilot clinical trials.
|
30930764 |
2019 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among the different classes of diabetic drugs, pioglitazone (PIO), a PPARγ agonist classed as an insulin sensitizer, is of the highest interest for AD management.
|
30738020 |
2019 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These first insights into the mechanisms through which PPARγ influences synaptic loss make a case for further exploration of the potential usefulness of PPARγ agonists in the prevention and treatment of synaptic pathology in AD.
|
31263400 |
2019 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results indicated MiR-128 knockout weakened AD-like performances, and reduced Aβ production and inflammatory responses by targeting PPARγ in AD mice.
|
30412727 |
2019 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings also improve our understanding of the role of PPARγ in hNSCs, and may aid in the development and implementation of new therapeutic strategies for the treatment of AD.
|
29964054 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
CTD_human |
Inhibition of miR-128 Abates Aβ-Mediated Cytotoxicity by Targeting PPAR-γ via NF-κB Inactivation in Primary Mouse Cortical Neurons and Neuro2a Cells.
|
30328325 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
PPARγ agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer's disease: in vitro and in vivo studies.
|
30271148 |
2018 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MiR-128 expression was upregulated and PPAR-γ expression was downregulated in plasma from AD patients and amyloid-β (Aβ)-treated primary mouse cortical neurons (MCN) and Neuro2a (N2a) cells.
|
30328325 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma (PPAR<i>γ</i>) agonists such as rosiglitazone and pioglitazone reduce amyloid and tau pathologies, inhibit neuroinflammation, and improve memory impairments in several rodent models and in humans with mild-to-moderate AD.
|
30420872 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Rationale:</b> It has been reported that peroxisome proliferator activated receptor γ (PPARγ) level decreases significantly in the brains of Alzheimer's disease (AD) patients and mice models, while the mechanism is unclear.
|
30128052 |
2018 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PPARγ activator rosiglitazone (RSZ) or AMPK activator AICAR increased the expression level of IDE and decreased Aβ levels in mice with AD and T2D.
|
29222348 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Donepezil is a first-line acetylcholinesterase inhibitor used for the treatment of AD that has been found, in addition to its potent acetylcholinesterase inhibitory effect, to act through other non-cholinergic mechanisms such as affecting mitochondrial biogenesis through peroxisome proliferator-activated receptor gamma coactivator (PGC1α).
|
29852870 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present review focusses on the thermodynamic implications in the reprogramming of cellular energy metabolism enabling in Alzheimer's disease (AD) through the opposite interplay of the molecular signaling pathways WNT/β-catenin and PPARγ.
|
29079469 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
So, nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) plays an important role in the treatment of AD.
|
27023226 |
2017 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The therapeutic efficacy of EGCG in AD may be derived from the up-regulation of PPARγ mRNA and protein expressions.
|
27889855 |
2017 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of PPARγ degradation and PERK/eIF2α phosphorylation are involved in the course, therefore suggesting that ICS II might be a promising potential compound for the treatment of AD.
|
28337142 |
2017 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To test the hypothesis that electroacupuncture (EA) confers therapeutic benefits through activation of PPAR-γ in a rat model of AD.
|
27401747 |
2017 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hence, these three bioactive lipids (resolvin E1, neuroprotectin D1 and hydroxy-linoleic acid) may be favourably considered as ideal drug candidates in therapeutic modulation of clinical conditions such as type 2 DM, Alzheimer's disease and other instances where PPARγ is a key player.
|
28109294 |
2017 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In previous studies, we have demonstrated the beneficial effects of classic PPARγ agonists on neuroprotection against Aβ oligomer neurotoxicity in a double transgenic mouse model of Alzheimer' disease (AD).
|
28655613 |
2017 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CBD suppresses, through activation of PPARγ, pro-inflammatory signaling and may be a potential new candidate for AD therapy.
|
28981597 |
2017 |
Alzheimer's Disease
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
PPARgamma agonists rescue increased phosphorylation of FGF14 at S226 in the Tg2576 mouse model of Alzheimer's disease.
|
28522250 |
2017 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Rosiglitazone, a peroxisome proliferator-activated receptor γ (PPAR-γ) agonist and anti-diabetic agent, may improve symptoms of AD.
|
28656081 |
2017 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
PPARγ-coactivator-1α gene transfer reduces neuronal loss and amyloid-β generation by reducing β-secretase in an Alzheimer's disease model.
|
27791018 |
2016 |